Ann Dermatol.  2016 Apr;28(2):269-270. 10.5021/ad.2016.28.2.269.

Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy

• Yamada S
• Kajihara I
• Johno T
• Fukushima
• Jinnin M
• Masunaga A
• Kohrogi H
• Ihn H

• KMID: 2171396
• DOI: http://doi.org/10.5021/ad.2016.28.2.269

Abstract

No abstract available.

MeSH Terms

Arthritis, Psoriatic*
Cryptococcosis*
Humans
Infliximab

Figure

• 

  Fig. 1 (A) Chest computed tomography showed multiple small nodules at the right middle lobe (circle). (B) Cytology of bronchoalveolar lavage fluid showed encapsulated yeasts (arrows), which is consistent with cryptococcosis species (Papanicolaou stain, ×400).

Reference

1. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med. 1981; 94:611–616.

2. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012; 50:3–13.

3. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004; 38:1261–1265.

4. Hirai F, Matsui T, Ishibashi Y, Higashi D, Futami K, Haraoka S, et al. Asymptomatic pulmonary cryptococcosis in a patient with Crohn's disease on infliximab: case report. Inflamm Bowel Dis. 2011; 17:1637–1638.

5. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun. 2002; 70:2959–2964.